As lockdown restrictions begin to ease, it’s time for pharma companies to lay out their plans for their return to ‘normal’ or to even redefine what their ‘normal’ will look like post-pandemic. Many pharma companies have already begun to lay out their plans for a more hybrid future working model which supports ...